18889881171
Kalkine 0
countryflagUS

ANI Pharmaceuticals Inc

Healthcare US ANIP

64.76USD
-0.43(0.66%)

Last update at 2025-07-15T16:50:00Z

Day Range

64.6265.72
LowHigh

52 Week Range

51.2470.81
LowHigh

Fundamentals

  • Previous Close 65.19
  • Market Cap1243.41M
  • Volume134766
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA82.12M
  • Revenue TTM555.46M
  • Revenue Per Share TTM28.91
  • Gross Profit TTM 177.60M
  • Diluted EPS TTM-0.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.66500M -56.05800M -25.96200M 3.16M 20.05M
Minority interest - - - - -
Net income -47.89600M -42.60300M -22.54800M 6.09M 15.49M
Selling general administrative 127.80M 84.29M 64.99M 55.84M 44.06M
Selling and marketing expenses - - - - -
Gross profit 177.60M 115.53M 121.32M 143.39M 128.55M
Reconciled depreciation 56.97M 47.25M 44.64M 44.61M 33.74M
Ebit -25.06400M -32.51200M -16.06400M 16.35M 34.81M
Ebitda 31.91M 14.74M 28.57M 60.81M 68.55M
Depreciation and amortization 56.97M 47.25M 44.64M 44.46M 33.74M
Non operating income net other 0.67M -4.34300M -0.49400M -0.22800M -0.55000M
Operating income -25.06400M -32.51200M -16.06400M 16.35M 35.36M
Other operating expenses 342.12M 244.31M 224.04M 190.12M 166.22M
Interest expense 28.05M 11.92M 9.45M 12.97M 14.76M
Tax provision -14.76900M -13.45500M -3.41400M -2.93700M 4.56M
Interest income - - - 12.97M 14.76M
Net interest income -28.05200M -11.92200M -9.45200M -12.96600M -14.75800M
Extraordinary items - - - - -
Non recurring 5.79M 11.12M 0.45M 0.07M -
Other items - - - - -
Income tax expense -14.76900M -13.45500M -3.41400M -2.93700M 4.56M
Total revenue 316.38M 216.14M 208.47M 206.55M 201.58M
Total operating expenses 203.33M 143.69M 136.89M 126.97M 93.19M
Cost of revenue 138.78M 100.61M 87.16M 63.15M 73.02M
Total other income expense net -37.60100M -23.54600M -9.89800M -13.19400M -0.55000M
Discontinued operations - - - - -
Net income from continuing ops -47.89600M -42.60300M -22.54800M 6.09M 15.49M
Net income applicable to common shares -49.52100M -42.79300M -22.54800M 6.09M 15.49M
Preferred stock and other adjustments 1.62M 0.19M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 904.42M 760.09M 771.60M 461.19M 456.79M
Intangible assets 209.01M 251.63M 294.12M 188.51M 180.39M
Earning assets - - - - -
Other current assets 25.22M 8.39M 11.26M 5.86M 5.07M
Total liab 471.67M 421.55M 412.86M 265.49M 244.00M
Total stockholder equity 432.75M 338.54M 358.74M 195.70M 212.79M
Deferred long term liab - 0.60M 0.80M 0.50M 0.80M
Other current liab 99.78M 69.28M 63.63M 53.98M 36.68M
Common stock 0.00200M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 24.85M 24.85M 24.85M 0.00100M 0.00100M
Retained earnings -80.13200M -97.28600M -47.76500M -4.97200M 17.58M
Other liab - 35.06M 31.02M 0.20M 0.00700M
Good will 28.22M 28.22M 27.89M 3.58M 3.58M
Other assets - 92.72M 75.14M 57.51M 44.58M
Cash 221.12M 48.23M 100.30M 7.86M 62.33M
Cash and equivalents - - - - -
Total current liabilities 145.48M 99.44M 87.54M 78.56M 61.68M
Current deferred revenue 8.16M - 0.09M 0.08M 0.45M
Net debt 94.21M 238.29M 187.07M 177.82M 123.42M
Short term debt 0.85M 0.85M 0.85M 13.24M 9.94M
Short long term debt 0.85M 0.85M 0.85M 13.24M 9.94M
Short long term debt total 315.33M 286.52M 287.37M 185.69M 185.75M
Other stockholder equity 479.17M 398.81M 384.71M 212.11M 200.08M
Property plant equipment - 43.25M 52.67M 41.27M 40.55M
Total current assets 519.62M 344.26M 321.77M 170.32M 187.69M
Long term investments - - - - -
Net tangible assets - 58.68M 36.73M 3.61M 28.82M
Short term investments - - - - -
Net receivables 162.08M 165.44M 128.53M 95.79M 72.13M
Long term debt 284.82M 285.67M 286.52M 172.44M 175.81M
Inventory 111.20M 105.36M 81.69M 60.80M 48.16M
Accounts payable 36.68M 29.30M 22.97M 11.26M 14.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.86M 12.17M -3.05500M -11.43700M -4.87100M
Additional paid in capital - - - - -
Common stock total equity - 0.00100M 0.00100M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -97.28600M -47.76500M -4.97200M 17.58M
Treasury stock - - - - -0.72300M
Accumulated amortization - - - - -
Non currrent assets other 6.07M 11.36M 7.21M 5.80M 6.25M
Deferred long term asset charges - - - - -
Non current assets total 384.81M 415.83M 449.82M 290.87M 269.09M
Capital lease obligations - - - - -
Long term debt total - - - - 175.81M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -15.73800M -105.48300M -68.32200M -27.54900M -27.37900M
Change to liabilities 4.88M 2.59M 2.69M -1.05900M 5.94M
Total cashflows from investing activities -15.73800M -105.48300M -68.32200M -27.54900M -27.37900M
Net borrowings -3.00000M 99.02M -0.53400M -121.45700M -28.93800M
Total cash from financing activities -5.12600M 194.59M -1.43900M 1.25M -27.81600M
Change to operating activities 4.36M -0.35300M 11.11M 1.43M 1.44M
Net income -47.89600M -42.60300M -22.54800M 6.09M 15.49M
Change in cash -52.06700M 92.43M -54.49400M 19.33M 11.88M
Begin period cash flow 105.30M 12.87M 67.36M 48.03M 36.15M
End period cash flow 53.23M 105.30M 12.87M 67.36M 48.03M
Total cash from operating activities -31.20300M 3.32M 15.27M 45.63M 67.07M
Issuance of capital stock 0.00000M 100.00M - - -
Depreciation 59.65M 47.25M 44.64M 44.61M 33.74M
Other cashflows from investing activities -6.86200M -102.92600M -62.18700M -20.91400M -21.63600M
Dividends paid -1.62500M -0.19000M 0.19M 0.19M 0.19M
Change to inventory -23.62600M 3.22M -2.75900M -7.66000M -0.37900M
Change to account receivables -36.91200M -5.54800M -23.66400M -7.28700M -4.74300M
Sale purchase of stock -1.95900M -0.89000M -1.52300M -1.03100M -0.65900M
Other cashflows from financing activities 1.46M 331.69M 15.62M 123.74M 1.78M
Change to netincome 0.32M -3.75500M 3.93M 2.48M 3.40M
Capital expenditures 16.45M 23.64M 68.32M 27.55M 10.91M
Change receivables -36.91200M -5.54800M -23.66400M -7.28700M -4.74300M
Cash flows other operating 8.42M -0.35300M 11.11M 1.43M 5.15M
Exchange rate changes - - - - -
Cash and cash equivalents changes -52.06700M 92.43M -54.49400M 19.33M 11.88M
Change in working capital -51.30000M -0.08400M -12.62800M -14.58100M 5.97M
Stock based compensation 14.60M 10.49M 12.94M 9.22M 6.78M
Other non cash items 8.99M 5.02M 6.07M 9.42M 10.27M
Free cash flow -47.65800M -20.31600M -53.05500M 18.08M 56.16M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANIP
ANI Pharmaceuticals Inc		 -0.43 0.66% 64.76 - 9.37 2.24 3.00 3.09 24.47
ZTS
Zoetis Inc		 -1.98 1.27% 153.67 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.16 0.62% 25.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.45 1.14% 125.37 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.3 1.99% 14.74 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals Inc

210 Main Street West, Baudette, MN, United States, 56623

Key Executives

Name Title Year Born
Mr. Nikhil Lalwani Pres, CEO & Director 1978
Mr. Stephen P. Carey CFO, Sr. VP of Fin. & Corp. Sec. 1971
Mr. James G. Marken Sr. VP of Operations & Product Devel. 1963
Mr. Christopher K. Mutz Head of Rare Disease 1972
Mr. Ori Gutwerg Sr. VP of Generics 1974
Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, COO of Novitium Operations & Director 1968
Ms. Meredith W. Cook Sr. VP, Gen. Counsel & Corp. Sec. NA
Mr. Chad Gassert Sr. VP of Corp. Devel. & Strategy 1976
Ms. Krista L. Davis Chief HR Officer NA
Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.